Advertisement

Topics

EC approves Sandoz’s Rixathon for blood cancer and immunological diseases

19:00 EDT 19 Jun 2017 | Pharmaceutical Technology

Novartis division Sandoz’s Rixathon (biosimilar rituximab) has received approval from the European Commission (EC) to treat blood cancers and immunological diseases in Europe.

Original Article: EC approves Sandoz’s Rixathon for blood cancer and immunological diseases

NEXT ARTICLE

More From BioPortfolio on "EC approves Sandoz’s Rixathon for blood cancer and immunological diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...